M. Majem Tarruella

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study

M.L. García de Paredes, F. del Moral González, Purificación Martínez del Prado et al. · Annals of Oncology · 2010 · 88 citations

Medicine, Neurology, Oncology +16

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Masahiro Tsuboi, Yi‐Long Wu, C Grohé et al. · Annals of Oncology · 2022 · 23 citations

Medicine, Oncology, Pharmacology +14

Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

Tetsuya Mitsudomi, M-J. Ahn, Lyudmila Bazhenova et al. · Annals of Oncology · 2017 · 17 citations

Medicine, Oncology, Pharmacology +17